{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:23:04Z","timestamp":1793784184372,"version":"4.6.1"},"reference-count":35,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Gabapentin and pregabalin are widely used in the management of neuropathic pain though their prescribing patterns, effectiveness, and safety profiles remain topics of ongoing research. This retrospective chart review analyzed the prevalence of gabapentinoid use in a chronic pain clinic over a one-year period from May 1, 2023, to April 30, 2024. The study examined patient records from four pain management physicians, focusing on those prescribed gabapentin or pregabalin. Of the 2,395 patients reviewed, 478 (19.96%) were prescribed gabapentin, while 236 (9.85%) received pregabalin. Combined, 714 patients (29.81%) were managed with either medication, highlighting the significant role gabapentinoids play in chronic pain treatment. The study found that gabapentin was prescribed more frequently than pregabalin. Although both medications are effective for neuropathic pain, their use comes with notable side effects, including dizziness, somnolence, and, in some cases, an increased risk of suicidal ideation. This review underscores the importance of careful patient monitoring and individualized treatment approaches when prescribing gabapentinoids. Future research across multiple sites and further stratification of patient demographics would enhance understanding of gabapentinoid use in clinical practice.<\/jats:p>","DOI":"10.64719\/pb.4510","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"26-36","source":"Crossref","is-referenced-by-count":10,"title":["Prescribing Patterns of Gabapentinoids in Chronic Pain Management: A Single Institution Retrospective Chart Review"],"prefix":"10.64719","volume":"55","author":[{"given":"Richard T","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand S","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker P","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace H","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amad","family":"Qadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant H","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranganathan","family":"Govindaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Honarmand A, Safavi M, Zare M. Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy. J Res Med Sci Off J Isfahan Univ Med Sci. 2011;16(8):1062\u20131069."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25(1):81\u2013104. doi: 10.1016\/S0149-2918(03)90011-7. doi:","DOI":"10.1016\/S0149-2918(03)90011-7"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Kneib CJ, Sibbett SH, Carrougher GJ, Muffley LA, Gibran NS, Mandell SP. The effects of early neuropathic pain control with gabapentin on long-term chronic pain and itch in burn patients. J Burn Care Res Off Publ Am Burn Assoc. 2019;40(4):457\u2013463. doi: 10.1093\/jbcr\/irz036. doi:","DOI":"10.1093\/jbcr\/irz036"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kanner AM, Ashman E, Gloss D et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):74\u201381. doi: 10.1212\/WNL.0000000000005755. doi:","DOI":"10.1212\/WNL.0000000000005755"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Aurora R. The treatment of restless legs syndrome and periodic limb movement disorder in adults\u2014an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses. [August 27, 2024];2012 August 1; Accessed. https:\/\/aasm.org\/resources\/practiceparameters\/treatmentrls.pdf.","DOI":"10.5665\/sleep.1986"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015;49(8):897\u2013906. doi: 10.1177\/1060028015585849. doi:","DOI":"10.1177\/1060028015585849"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Ahmed S, Bachu R, Kotapati P et al. Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review. Front Psychiatry. 2019;10:228. doi: 10.3389\/fpsyt.2019.00228. doi:","DOI":"10.3389\/fpsyt.2019.00228"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zesiewicz TA, Elble RJ, Louis ED et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology. 2011;77(19):1752\u20131755. doi: 10.1212\/WNL.0b013e318236f0fd. doi:","DOI":"10.1212\/WNL.0b013e318236f0fd"},{"key":"ref9","unstructured":"Yasaei R, Katta S, Patel P, Saadabadi A. Gabapentin. [August 30, 2024];2024 In: StatPearls. StatPearls Publishing. Accessed. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493228\/"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Arnold LM, Goldenberg DL, Stanford SB et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336\u20131344. doi: 10.1002\/art.22457. doi:","DOI":"10.1002\/art.22457"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Raouf M, Atkinson TJ, Crumb MW, Fudin J. Rational dosing of gabapentin and pregabalin in chronic kidney disease. J Pain Res. 2017;10:275\u2013278. doi: 10.2147\/JPR.S130942. doi:","DOI":"10.2147\/JPR.S130942"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Vickers-Smith R, Sun J, Charnigo RJ, Lofwall MR, Walsh SL, Havens JR. Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug Alcohol Depend. 2020;206:107709. doi: 10.1016\/j.drugalcdep.2019.107709. doi:","DOI":"10.1016\/j.drugalcdep.2019.107709"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru J Fac Pharm Tehran Univ Med Sci. 2019;27(1):149\u2013158. doi: 10.1007\/s40199-019-00257-4. doi:","DOI":"10.1007\/s40199-019-00257-4"},{"key":"ref14","unstructured":"Bragg S, Marrison ST, Haley S. Diabetic peripheral neuropathy: prevention and treatment. Am Fam Physician. 2024;109(3):226\u2013232."},{"key":"ref15","unstructured":"Cross AL, Viswanath O, Sherman AL. Pregabalin. [August 30, 2024];2024 In: StatPearls. StatPearls Publishing. Accessed. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470341\/"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137\u2013150. doi: 10.1016\/j.eplepsyres.2006.09.008. doi:","DOI":"10.1016\/j.eplepsyres.2006.09.008"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13\u201318. doi: 10.1111\/j.0013-9580.2004.455003.x. doi:","DOI":"10.1111\/j.0013-9580.2004.455003.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Moulin D, Boulanger A, Clark AJ et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328\u2013335. doi: 10.1155\/2014\/754693. doi:","DOI":"10.1155\/2014\/754693"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. Korean J Pain. 2020;33(1):3\u201312. doi: 10.3344\/kjp.2020.33.1.3. doi:","DOI":"10.3344\/kjp.2020.33.1.3"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Robertson K, Marshman LAG, Plummer D, Downs E. Effect of gabapentin vs pregabalin on pain intensity in adults with chronic sciatica: a randomized clinical trial. JAMA Neurol. 2019;76(1):28\u201334. doi: 10.1001\/jamaneurol.2018.3077. doi:","DOI":"10.1001\/jamaneurol.2018.3077"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Gammoh O, Al-Smadi A, Shawagfeh MQ et al. The clinical difference between gabapentin and pregabalin: data from a pilot comparative trial. Rev Recent Clin Trials. 2021;16(3):279\u2013287. doi: 10.2174\/1574887116666210201110507. doi:","DOI":"10.2174\/1574887116666210201110507"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1\u201332. doi: 10.1146\/annurev.neuro.051508.135531. doi:","DOI":"10.1146\/annurev.neuro.051508.135531"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281\u2013289. doi: 10.1016\/j.jpain.2005.11.008. doi:","DOI":"10.1016\/j.jpain.2005.11.008"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152(12):2836\u20132843. doi: 10.1016\/j.pain.2011.09.014. doi:","DOI":"10.1016\/j.pain.2011.09.014"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med Malden Mass. 2010;11(3):456\u2013465. doi: 10.1111\/j.1526-4637.2009.00796.x. doi:","DOI":"10.1111\/j.1526-4637.2009.00796.x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Taguchi T, Nozawa K, Parsons B et al. Effectiveness of pregabalin for treatment of chronic cervical radiculopathy with upper limb radiating pain: an 8-week, multicenter prospective observational study in Japanese primary care settings. J Pain Res. 2019;12:1411\u20131424. doi: 10.2147\/JPR.S191906. doi:","DOI":"10.2147\/JPR.S191906"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Lo YL, Cheong PWT, George JM et al. Pregabalin and Radicular Pain Study (PARPS) for cervical spondylosis in a multiracial Asian Population. J Clin Med Res. 2014;6(1):66\u201371. doi: 10.4021\/jocmr879w. doi:","DOI":"10.4021\/jocmr879w"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Cohen SP, Hayek S, Semenov Y et al. Epidural steroid injections, conservative treatment, or combination treatment for cervical radicular pain: a multicenter, randomized, comparative-effectiveness study. Anesthesiology. 2014;121(5):1045\u20131055. doi: 10.1097\/ALN.0000000000000409. doi:","DOI":"10.1097\/ALN.0000000000000409"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Kwon DY, Kwak SG, Kim DH. Comparing the therapeutic effects of pregabalin and gabapentin after transforaminal epidural nerve block in lumbar radiculopathy. Medicine (Baltimore). 2022;101(32):e29370. doi: 10.1097\/MD.0000000000029370. doi:","DOI":"10.1097\/MD.0000000000029370"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Athanasakis K, Petrakis I, Karampli E, Vitsou E, Lyras L, Kyriopoulos J. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting. BMC Neurol. 2013;13:56. doi: 10.1186\/1471-2377-13-56. doi:","DOI":"10.1186\/1471-2377-13-56"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Meaadi J, Obara I, Eldabe S, Nazar H. The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials. Int J Clin Pharm. 2023;45(3):556\u2013565. doi: 10.1007\/s11096-022-01528-y. doi:","DOI":"10.1007\/s11096-022-01528-y"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Nwankwo A, Koyyalagunta D, Huh B, D\u2019Souza RS, Javed S. A comprehensive review of the typical and atypical side effects of gabapentin. Pain Pract Off J World Inst Pain. 2024 July 1; doi: 10.1111\/papr.13400. Published online. doi:","DOI":"10.1111\/papr.13400"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Murphy R, McGuinness D, Hallahan B. Pregabalin-induced sexual disinhibition. Ir J Psychol Med. 2020;37(1):55\u201358. doi: 10.1017\/ipm.2017.5. doi:","DOI":"10.1017\/ipm.2017.5"},{"key":"ref34","unstructured":"DailyMed\u2013NEURONTIN- gabapentin capsule NEURONTIN- gabapentin tablet, film coated NEURONTIN- gabapentin solution. [September 30, 2024]; Accessed. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Molero Y, Larsson H, D\u2019Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:l2147. doi: 10.1136\/bmj.l2147. doi:","DOI":"10.1136\/bmj.l2147"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:05Z","timestamp":1791315185000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/prescribing-patterns-of-gabapentinoids-in-chronic-pain-management-a-single-institution-retrospective-chart-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4510","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}